Wandong Medical reports significant net profit decline in Q3 2025

Beijing Wandong Medical Technology Co., Ltd. announced a decrease in its third-quarter 2025 operating revenue, which stood at CNY 345,179,582.58, a 12.17% decline compared to the same period last year. The company recorded a profit loss of CNY 79,241,287.34, representing a 315.69% decrease. Net profit attributable to shareholders also plummeted by 353.32% to CNY -78,508,463.45.

For the first three quarters of 2025, the company's cumulative operating revenue reached CNY 1,188,509,072.63, an increase of 8.73%. However, the cumulative net profit attributable to shareholders saw a decline of 123.51%, totaling CNY -27,209,818.77. The diluted earnings per share for the nine-month period were CNY -0.039.

The company attributed these changes primarily to shifts in sales strategies, delayed delivery of centralized procurement projects, which impacted gross profit margins, and a continuous increase in research and development investments. Operating cash flow also experienced a significant decline, falling by 1691.43% to CNY -403,852,005.54 year-to-date, due to sales strategy changes and extended collection periods.